- Home
- XENE vs HCM Comparison
XENE vs HCM Comparison
Compare XENE & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XENE
- HCM
- Stock Information
- Founded
- XENE 1996
- HCM 2000
- Country
- XENE Canada
- HCM Hong Kong
- Employees
- XENE N/A
- HCM N/A
- Industry
- XENE Biotechnology: Pharmaceutical Preparations
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- XENE Health Care
- HCM Health Care
- Exchange
- XENE Nasdaq
- HCM Nasdaq
- Market Cap
- XENE 2.4B
- HCM 2.5B
- IPO Year
- XENE 2014
- HCM N/A
- Fundamental
- Price
- XENE $32.63
- HCM $16.23
- Analyst Decision
- XENE Strong Buy
- HCM Hold
- Analyst Count
- XENE 11
- HCM 1
- Target Price
- XENE $54.82
- HCM $19.00
- AVG Volume (30 Days)
- XENE 1.5M
- HCM 73.3K
- Earning Date
- XENE 08-07-2025
- HCM 08-07-2025
- Dividend Yield
- XENE N/A
- HCM N/A
- EPS Growth
- XENE N/A
- HCM N/A
- EPS
- XENE N/A
- HCM 0.04
- Revenue
- XENE $7,500,000.00
- HCM $630,201,000.00
- Revenue This Year
- XENE N/A
- HCM $14.86
- Revenue Next Year
- XENE $253.71
- HCM $19.54
- P/E Ratio
- XENE N/A
- HCM $72.72
- Revenue Growth
- XENE N/A
- HCM N/A
- 52 Week Low
- XENE $26.74
- HCM $11.51
- 52 Week High
- XENE $46.00
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- XENE 51.18
- HCM 55.79
- Support Level
- XENE $31.22
- HCM $15.41
- Resistance Level
- XENE $33.51
- HCM $16.42
- Average True Range (ATR)
- XENE 1.18
- HCM 0.30
- MACD
- XENE 0.04
- HCM 0.01
- Stochastic Oscillator
- XENE 45.62
- HCM 75.64
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.